Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.1352W HIGH $54.32
Volume
45.63 K
Value Traded
25.07 M
Short % Float
8.68%
-3.43%Week
+2.06%1 Month
+78.26%3 Month
+76.73%6 Month
+33.14%5 Year
+33.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.18 B
EPS (TTM)
-1.36
P/E Ratio
-
Ent. Value
3.98 B
Total Shares
86.95 M
Float Shares
64.83 M
Insiders
25.44%
Institutions
82.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HTFL Catalyst Timeline
Dated clinical, regulatory and corporate events for Heartflow, Inc.
Past FDA Catalysts and PDUFA Decisions
How HTFL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Heartflow, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HTFL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Heartflow FFR CT Analysis | coronary artery disease | 2026-08-28 | 44%; 22% [57/263] Heartflow vs. 39% [103/265] CCTA alone; p < 0.001; 43% [114/263] Heartflow vs. 61% [161/265] CCTA alone; p < 0.001; 20% [52/263] vs. 20% [53/265]; p = 0.948Read More | Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly HalfRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Verghese VikramOfficer (Chief Financial Officer) | Sell | -16,766 155,183 held | $50.75 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HTFL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 14.7 % (-35.8 %) | 247.87 M | 8.45 M | -19.14% ( -2.00 M) |
HTFL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HTFL ranks across every disease it competes in
Competitive Position is a premium feature
See how HTFL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHTFL News
HTFLLate Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
Heartflow, Inc. announced that its FFR CT Analysis significantly reduces unnecessary invasive heart procedures by 44%, according to results from the FUSION trial presented at the ESC Congress 2026. The trial demonstrated that combining Heartflow's analysis with standard CCTA scans enhances diagnostic accuracy and efficiency. This independent study reinforces the value of Heartflow's technology in clinical practice.
Read more →HTFLHeartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
Heartflow, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will feature a fireside chat with a presentation and Q&A session. Heartflow is recognized for its AI technology in diagnosing coronary artery disease, supported by a vast dataset and numerous clinical validations.
Read more →HTFL▲ +35.7%on this news· ran to +47% by day 3
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Heartflow, Inc. reported a strong second quarter for 2026, with total revenue reaching $64.1 million, marking a 48% increase from the previous year. The company raised its annual revenue guidance to between $246 million and $250 million, reflecting confidence in its growth trajectory. Despite a net operating loss of $17.9 million, improvements in gross margins and operational efficiency were noted, driven by its AI technology in diagnosing coronary artery disease.
Read more →HTFLHeartflow to Report Second Quarter 2026 Financial Results on August 13, 2026
Heartflow, Inc. will announce its second quarter 2026 financial results on August 13, 2026, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results. Heartflow is recognized for its AI technology in coronary artery disease, with a significant global presence and extensive clinical validation.
Read more →HTFL▲ +6%on this news
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
Heartflow, Inc. announced the presentation of new data at the SCCT 2026 Annual Scientific Meeting, highlighting the effectiveness of its AI-powered Heartflow Plaque Analysis. The data, derived from over 36,000 patients, demonstrate that traditional calcium scoring may miss significant non-calcified plaque, which Heartflow's technology can accurately detect. The newly launched Heartflow Plaque Staging tool is integrated into every analysis, allowing for precise risk stratification and improved patient management.
Read more →HTFLHeartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Heartflow, Inc. reported its first quarter 2026 financial results, revealing a significant 41% increase in total revenue year-over-year, primarily driven by the growth of its FFRCT business. The company also raised its full year guidance, emphasizing its leadership position in AI technology for coronary artery disease. Despite the revenue growth, Heartflow experienced an increase in net operating loss to $29.5 million, indicating challenges in cost management. The overall expansion of the company's AI-driven solutions suggests positive momentum moving forward.
Read more →HTFLThe Future of Intoxication Detection May Be in Your Voice
MindBio Therapeutics is developing a novel AI-driven platform that utilizes voice analysis to detect drug and alcohol intoxication in real-time. This innovative approach aims to address the limitations of traditional testing methods, which are often invasive and slow. The company is targeting a significant market in workplace safety and substance testing, potentially transforming public health and regulatory enforcement.
Read more →HTFL▼ -5.1%on this news
Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026
Heartflow, Inc. will announce its financial results for Q1 2026 on May 14, 2026, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results. The company continues to enhance its AI technology for coronary artery disease, which has been adopted by numerous institutions worldwide.
Read more →HTFLHeartflow Files Patent Infringement Lawsuit Against Cleerly
Heartflow, Inc. has filed a patent infringement lawsuit against Cleerly, Inc. in Texas, claiming that Cleerly's products infringe on six of its patents. The lawsuit seeks permanent injunctive relief and damages due to unauthorized use of Heartflow's technology. Heartflow emphasizes its commitment to protecting its innovations, which have benefited over 600,000 patients worldwide.
Read more →HTFL▲ +13.1%on this news
Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results
Heartflow, Inc. reported impressive financial results for the fourth quarter and full year of 2025, with total revenue reaching $176 million, representing a 40% increase year-over-year. The company highlighted strong growth in U.S. revenue, supported by increased adoption of its Heartflow Platform, and noted improvements in gross margins. However, the net operating loss for the quarter increased compared to the previous year, amidst rising overall operating expenses. The company's guidance for 2026 remains optimistic, indicating confidence in continued growth and innovation.
Read more →HTFL▼ -16.5%on this news
Heartflow Expands GAMEFILM Registry to NBA and NHL Alumni, Precisely Measuring Heart Disease Risk in Former Professional Athletes
Heartflow, Inc. has expanded its GAMEFILM Registry to include former NBA and NHL players, building on its initial success with NFL athletes. This initiative aims to assess heart disease risk among professional athletes using advanced AI technology. The registry seeks to enroll up to 300 former players to enhance understanding of cardiovascular health in this population. Heartflow's efforts highlight the importance of proactive heart care in preventing serious health issues.
Read more →HTFLHeartflow Investor Presentation January 2026 Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigatio
HeartFlow presented forward-looking statements concerning its business strategy, market growth, and operational expectations. The company outlined significant financial metrics, noting $162 million in revenue for the last twelve months and 41% year-over-year growth. However, it also emphasized notable risks, including reliance on its main product and uncertainties in market adoption. Despite this, HeartFlow remains optimistic about its leadership in AI technology for coronary artery disease and its potential market expansion.
Read more →HTFLHeartflow to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Heartflow, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The event will showcase Heartflow's advancements in AI technology for coronary artery disease, highlighting its impact on cardiovascular care. The presentation will be accessible live and archived on their website.
Read more →HTFLHeartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
Heartflow, Inc. announced new analyses from the FISH&CHIPS study, showcasing the effectiveness of Heartflow FFRCTAnalysis in improving diagnostic decisions and predicting cardiovascular events in over 90,000 patients. The study demonstrated substantial cost savings and reduced unnecessary tests, highlighting the clinical and economic value of this AI-powered technology in managing coronary artery disease.
Read more →HTFLHeartflow Reports Third Quarter 2025 Financial Results
Heartflow, Inc. (Nasdaq: HTFL) reported its financial results for the third quarter of 2025, revealing a total revenue of $46.3 million, marking a 41% increase year-over-year. The company initiated full-year revenue guidance, expecting between $173.0 million and $173.5 million for 2025. Despite the positive growth, Heartflow recorded a net operating loss of $15.1 million. The increased physician interest in Heartflow's Plaque Analysis and recent commercial coverages are seen as promising signs for future growth.
Read more →About Heartflow, Inc.
Headquarters135 MAIN STREET, SUITE 1000, SAN FRANCISCO, CA, 94105
BIOPHARMAWATCH ELITE PLUS
Trade the next HTFL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime